focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes John, it did look that way for a while! I was bullish in Skyeharma all those years ago too, and still remain confident there is significant potential for Vectura…. just for the patient! Hopefully the new CEO will build a step change in performance once he has his feet firmly under the table, and the rewards will follow...
Thought we'd turned a corner for a bit! Ah well, at least near 17 years teaches you patience
Mac
Snap, 23/04/2003, 8056 Skypharma Ord 10p shares!
Looks like we have a wait for the GSK award - potentially until Q1 2021, assuming the award is upheld, given GSK's appeal.
Regardless, looks like a reasonable year in 2019, and potentially nice growth in 2020, albeit with increased cash cost as the business refocuses with the new CEO. Having been here for 16 years and still waiting for full value, I guess a few more years won't hurt...… good luck to us all!
I have also been here many years and wish i was a lawyer rather than an investor!
Was wondering about the uptick over the last few days. Decided to crystallise the loss in my non ISA holdings and buy them back (plus a few more) into my ISA. Its worked so far! Maybe my subconscious thinks big things are afoot...….
I've been a holder of this share since the Skypharma days. Frankly I deserve a long service award. A carriage clock would be nice.
JP Morgan have uplifted their target for Vec to 120p & we are one of their small cap favoured choices for 2020.
Hopefully the recovery in our SP fuelled by positive newsflow & continued modest share buy backs over the year & our new CEO should set his stall out in the trading update dyue in the next couple of weeks ,following a couple of months of his review of every aspect of our business.
To answer my own question, it looks like one-year, so that would give them potentially until 2nd May 2020 should they want to drag it out. The second award, also open to appeal, was on 12th September this year - though that is a further award based on the original one so would likely dependent on the status of the first. Regardless, it potentially opens the door for delay to September 2020. However, hopefully, sense will prevail and GSK will pay up and close the chapter in this fiscal year - guess we'll find out soon enough....
Anyone know how long GSK would have before their right to appeal the award against them lapses? I have read through their 2018 annual report and quarterly updates for this year, and can find no specific reference to the Vectura action, though did note that they have increased the provision for legal action from GBP200m to GBP400m in the current year. Though that does cover a multitude of legal cases currently proceeding against them, so may not be immediately cause for cheer. I'm assuming, if they decide to pay up without appeal, it will be in this years financial accounts, and therefore likely to be paid in the next 3-4 weeks. Unless they appeal at the very last moment to drag out as long as possible?
Anyone know more about these things than me? Be a great Christmas present to get $100m imminently, plus royalty revenues to first half next year and will surely give the share price a much needed boost!
Would it not make sense for GSK to buy VEC so they don’t have to pay us the fine for infringing on VEC copyright and de-risk against Hikma re-submitting the generic Advair, kill two birds with one stone and all that.
Maybe not as much riding on this after the first knock back, due to the time lost, but nevertheless it would certainly be a morale booster if it passed at the second time of asking.
Hikma have a great ongoing relationship with the FDA - all looks good.
Great to see it resubmitted & lets hope that it is approved quickly & launched into US market next year & lets also hope it boosts our SP
Looks like a good appointment to me as he has a solid track record & is taking over as CEO of a cash rich company with interesting developments in hand .Hopefully his timing will prove to be perfect as our SP continues to recover -supported by the first buy back which started modestly yesterday.A further excellent sign would be his investing some his own cash in our shares ,rather than relying on freebies
The market doesn't seem impressed by our new CEO hardly a glimmer of a response, reading through his background he seems a good fit and a capable guy, early days but if GSK just pay up without a fight that should see off to a flying start.
The special dividend of 6p per share is due to be paid today - has anyone received it?
Wondering anyone know where the allocated shares go after the special div/consolidation?
The special divi is just a capital release really. The consolidate the shares in issue to maintain the share price. Hopefully the price will go higher after consolidation, been woeful share performance for a long term holder like me
today is last day to catch dividends I’m in at this price.....this is cheap for 6p dividends and them consolidating the share price.
Wondering if this is still worth buying for the dividends? I know tomorrow is the last day with Monday being ex-div according to the Ventura RNS. Can’t get my head around all this taking one of your shares to consolidate business and ex div on Monday all a little weird for me.....
Webstar - many thanks.
Read the RNS dated 10th Sept - explains all
The Board has announced that a consolidation based on 12 shares for 13 wef 14 October 2019.
This could result in the loss of about one twelfth of the value of holdings and I wonder if the Board plans to compensate shareholders for this loss?.
There was a lot of talk about generic competition to GSKs Advair from Vectura and Mylan. Both were being rejected by the FDA. I believe Mylan got approval eventually. What happened to Vecturas offering, if Mylan managed it why couldn't we?
I presume its one reason these shares remain where they are, and have been for some considerable time.